Search

Poractant alfa

It is used to treat Respiratory Distress Syndrome (RDS) in premature infants with an endogenous pulmonary surfactant deficiency. … Poractant alfa is a pulmonary surfactant marketed as Curosurf in the United States and Canada.

Fexofenadine

Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. … [L4269] It is selective for the H₁ receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier[L10779] - this is in contrast to previous first-generation

Esketamine

The FDA approved ketamine (Ketalar) in 1970. … [L5593] Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications

Metreleptin

in food intake. … [L41315] In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized

Ticagrelor

[A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010. … Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y₁₂ receptor antagonism.

Cefiderocol

[L10893] It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available. … [A189150] A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.

Pindolol

[A231059] Research into pindolol's use in the treatment of hypertension began in the early 1970s.[A231064] Pindolol was granted FDA approval on 3 September 1982.[L32348] … Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension.

Turoctocog alfa pegol

This modification to the general turoctocog alfa rFVIII structure makes N8-GP an extended half-life factor VIII molecule for factor VIII replacement therapy in patients with factor VIII deficiency, or … It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104].

Cevimeline

Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3.

Haemagglutinin-strain A(H3N2)